Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Go back to Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis| Enliven Marketing Technologies Corporation (NASDAQ: ENLV) | Delayed: 4.36 -0.23 (5.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.59 | 52 Week High | $0.94 | |||
| Open | $4.52 | 52 Week Low | $0.47 | |||
| Day High | $4.61 | P/E | N/A | |||
| Day Low | $4.30 | EPS | $-0.11 | |||
| Volume | 130,624 | |||||

